clinical trial · NCT07416162
A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy
Paroxysmal Nocturnal HemoglobinuriaC3 Glomerulopathy
brief summary
This is a post-marketing surveillance study conducted as part of the Risk Management Plan (RMP) for South Korea, to evaluate the safety and effectiveness of iptacopan in real-world clinical settings for the treatment of either PNH or C3G in Korean patients. Prospective data will be collected from patient medical records to address the objectives for all eligible populations.
started
Jul 31, 2026
primary completion
Feb 1, 2029
completion
Feb 1, 2029
last updated
Feb 18, 2026
official title
A Post-marketing Surveillance of Fabhalta® (Iptacopan) in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) or C3 Glomerulopathy (C3G)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol